Gastric Cancer

, Volume 22, Issue 5, pp 955–966 | Cite as

Oncostatin M receptor, positively regulated by SP1, promotes gastric cancer growth and metastasis upon treatment with Oncostatin M

  • Zhenjia Yu
  • Zhen Li
  • Chenchen Wang
  • Tao Pan
  • Xinyu Chang
  • Xiaofeng Wang
  • Quan Zhou
  • Xiongyan Wu
  • Jianfang Li
  • Jinping Zhang
  • Bingya Liu
  • Zhenggang ZhuEmail author
  • Liping SuEmail author
Original Article



Oncostatin M receptor (OSMR) is a member of the interleukin 6 (IL-6) receptor family that transduces signaling events of Oncostatin M (OSM). OSM–OSMR signaling plays a key role in inflammation and cancer progression. However, the role of OSM–OSMR in gastric cancer (GC) is still unknown.


OSMR expression in GC was determined by real-time PCR (RT-PCR), immunohistochemistry (IHC) and Western blot. The effects of OSM–OSMR on GC cell proliferation, migration, invasion, and epithelial–mesenchymal transition (EMT) in vitro and metastasis in vivo were examined. The pathways underlying OSM–OSMR signaling were explored by Western blot. Regulatory mechanism between SP1 and OSMR was explored in vitro.


OSMR was highly expressed in GC tissues and its expression level was closely associated with age, T stage, Lauren classification, lymph node metastasis, TNM stage and worse prognosis of patients with GC. Knockdown of OSMR expression in GC cells significantly inhibited cell proliferation, migration, invasion, and EMT in vitro, as well as tumorigenesis and peritoneal metastasis in vivo induced by OSM. These effects mediated by OSM–OSMR were dependent on the activation of STAT3/FAK/Src signaling. SP1 could bind to the promoter region of human OSMR gene from − 255 to − 246 bp, and transcriptionally regulated OSMR overexpression in GC cells.


OSM–OSMR contributes to GC progression through activating STAT3/FAK/Src signaling, and OSMR is transcriptionally activated by SP1.


Oncostatin M Gastric cancer Tumorigenesis Metastasis 



We thank LetPub ( for the linguistic assistance during the preparation of this manuscript. This research was funded by National Natural Scientific Funding of China [Nos. 81572798, 81672822, 81871902 and 81871904] and Shanghai Municipal Education Commission-Gaofeng Clinical Medicine Grant Support [20152505].

Supplementary material

10120_2019_934_MOESM1_ESM.docx (234 kb)
Supplementary material 1 (DOCX 234 KB)


  1. 1.
    Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87–108.CrossRefGoogle Scholar
  2. 2.
    Yang L, Zheng R, Wang N, Yuan Y, Liu S, Li H, et al. Incidence and mortality of stomach cancer in China, 2014. Chin J Cancer Res. 2018;30(3):291–8.CrossRefGoogle Scholar
  3. 3.
    Hermanns HM. Oncostatin M and interleukin-31: Cytokines, receptors, signal transduction and physiology. Cytokine Growth Factor Rev. 2015;26(5):545–58.CrossRefGoogle Scholar
  4. 4.
    Kortylewski M, Heinrich PC, Mackiewicz A, Schniertshauer U, Klingmuller U, Nakajima K, et al. Interleukin-6 and Oncostatin M-induced growth inhibition of human A375 melanoma cells is STAT-dependent and involves upregulation of the cyclin-dependent kinase inhibitor p27/Kip1. Oncogene. 1999;18(25):3742–53.CrossRefGoogle Scholar
  5. 5.
    Pan CM, Wang ML, Chiou SH, Chen HY, Wu CW. Oncostatin M suppresses metastasis of lung adenocarcinoma by inhibiting SLUG expression through coordination of STATs and PIASs signalings. Oncotarget. 2016;7(37):60395–406.Google Scholar
  6. 6.
    Douglas AM, Grant SL, Goss GA, Clouston DR, Sutherland RL, Begley CG. Oncostatin M induces the differentiation of breast cancer cells. Int J Cancer. 1998;75(1):64–73.CrossRefGoogle Scholar
  7. 7.
    Halfter H, Lotfi R, Westermann R, Young P, Ringelstein EB, Stogbauer FT. Inhibition of growth and induction of differentiation of glioma cell lines by oncostatin M (OSM). Growth Factors. 1998;15(2):135–47.CrossRefGoogle Scholar
  8. 8.
    Lim SY, Ahn SH, Park H, Lee J, Choi K, Choi C, et al. Transcriptional regulation of adrenomedullin by oncostatin M in human astroglioma cells: implications for tumor invasion and migration. Sci Rep. 2014;4:6444.CrossRefGoogle Scholar
  9. 9.
    Caffarel MM, Coleman N. Oncostatin M receptor is a novel therapeutic target in cervical squamous cell carcinoma. J Pathol. 2014;232(4):386–90.CrossRefGoogle Scholar
  10. 10.
    Junnila S, Kokkola A, Karjalainen-Lindsberg ML, Puolakkainen P, Monni O. Genome-wide gene copy number and expression analysis of primary gastric tumors and gastric cancer cell lines. BMC Cancer. 2010;10:73.CrossRefGoogle Scholar
  11. 11.
    Zhou Q, Wang X, Yu Z, Wu X, Chen X, Li J, et al. Transducin (beta)-like 1 X-linked receptor 1 promotes gastric cancer progression via the ERK1/2 pathway. Oncogene. 2017;36(13):1873–86.CrossRefGoogle Scholar
  12. 12.
    Wang X, Zhou Q, Yu Z, Wu X, Chen X, Li J, et al. Cancer-associated fibroblast-derived Lumican promotes gastric cancer progression via the integrin beta1-FAK signaling pathway. Int J Cancer. 2017;141(5):998–1010.CrossRefGoogle Scholar
  13. 13.
    Szasz AM, Lanczky A, Nagy A, Forster S, Hark K, Green JE, et al. Cross-validation of survival associated biomarkers in gastric cancer using transcriptomic data of 1,065 patients. Oncotarget. 2016;7(31):49322–33.CrossRefGoogle Scholar
  14. 14.
    Vasaikar SV, Straub P, Wang J, Zhang B. LinkedOmics: analyzing multi-omics data within and across 32 cancer types. Nucleic Acids Res. 2018;46(D1):D956-D63.CrossRefGoogle Scholar
  15. 15.
    Lee BY, Timpson P, Horvath LG, Daly RJ. FAK signaling in human cancer as a target for therapeutics. Pharmacol Ther. 2015;146:132–49.CrossRefGoogle Scholar
  16. 16.
    Patel A, Sabbineni H, Clarke A, Somanath PR. Novel roles of Src in cancer cell epithelial-to-mesenchymal transition, vascular permeability, microinvasion and metastasis. Life Sci. 2016;157:52–61.CrossRefGoogle Scholar
  17. 17.
    Beishline K, Azizkhan-Clifford J. Sp1 and the ‘hallmarks of cancer’. FEBS J. 2015;282(2):224–58.CrossRefGoogle Scholar
  18. 18.
    West NR, Murphy LC, Watson PH. Oncostatin M suppresses oestrogen receptor-alpha expression and is associated with poor outcome in human breast cancer. Endocr Relat Cancer. 2012;19(2):181–95.CrossRefGoogle Scholar
  19. 19.
    Tanaka M, Miyajima A. Oncostatin M. a multifunctional cytokine. Rev Physiol Biochem Pharmacol. 2003;149:39–52.CrossRefGoogle Scholar
  20. 20.
    Godoy-Tundidor S, Cavarretta IT, Fuchs D, Fiechtl M, Steiner H, Friedbichler K, et al. Interleukin-6 and oncostatin M stimulation of proliferation of prostate cancer 22Rv1 cells through the signaling pathways of p38 mitogen-activated protein kinase and phosphatidylinositol 3-kinase. Prostate. 2005;64(2):209–16.CrossRefGoogle Scholar
  21. 21.
    Chen Y, Xia X, Wang S, Wu X, Zhang J, Zhou Y, et al. High FAK combined with low JWA expression: clinical prognostic and predictive role for adjuvant fluorouracil-leucovorin-oxaliplatin treatment in resectable gastric cancer patients. J Gastroenterol. 2013;48(9):1034–44.CrossRefGoogle Scholar
  22. 22.
    Hiscox S, Jordan NJ, Morgan L, Green TP, Nicholson RI. Src kinase promotes adhesion-independent activation of FAK and enhances cellular migration in tamoxifen-resistant breast cancer cells. Clin Exp Metastasis. 2007;24(3):157–67.CrossRefGoogle Scholar
  23. 23.
    Macha MA, Rachagani S, Gupta S, Pai P, Ponnusamy MP, Batra SK, et al. Guggulsterone decreases proliferation and metastatic behavior of pancreatic cancer cells by modulating JAK/STAT and Src/FAK signaling. Cancer Lett. 2013;341(2):166–77.CrossRefGoogle Scholar
  24. 24.
    Xu XW, Pan CW, Yang XM, Zhou L, Zheng ZQ, Li DC. SP1 reduces autophagic flux through activating p62 in gastric cancer cells. Mol Med Rep. 2018;17(3):4633–8.Google Scholar
  25. 25.
    West NR, Hegazy AN, Owens BMJ, Bullers SJ, Linggi B, Buonocore S, et al. Oncostatin M drives intestinal inflammation and predicts response to tumor necrosis factor-neutralizing therapy in patients with inflammatory bowel disease. Nat Med. 2017;23(5):579–89.CrossRefGoogle Scholar

Copyright information

© The International Gastric Cancer Association and The Japanese Gastric Cancer Association 2019

Authors and Affiliations

  1. 1.Shanghai Key Laboratory of Gastric Neoplasms, Shanghai Institute of Digestive Surgery, Department of SurgeryRuijin Hospital, Shanghai Jiao Tong University School of MedicineShanghaiChina
  2. 2.State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Renji HospitalShanghai Jiao Tong University School of MedicineShanghaiChina
  3. 3.Department of General Surgery, First People’s HospitalShanghai General Hospital, Shanghai Jiao Tong University School of MedicineShanghaiChina
  4. 4.Institute of Biology and Medical SciencesSoochow UniversitySuzhouChina

Personalised recommendations